Our Research

Rhythm’s translational research efforts are focused on deepening the understanding of melanocortin-4 receptor (MC4R) pathway-related rare genetic disorders of obesity.

Rhythm’s approach to these disorders is built upon a foundational DNA sequencing infrastructure with de-identified samples from more than 30,000 individuals living with severe obesity, believed to be one of the largest databases of its kind. Importantly, this unique resource fuels Rhythm’s focus and understanding of rare genetic disorders of obesity caused by deficiencies within the MC4R pathway, which are distinct from general obesity.

Rhythm’s DNA Sequencing Data Streams

Genetic testing can play an important role in diagnosing many rare genetic disorders of obesity, however some can be diagnosed by clinical features alone (e.g., Bardet-Biedl syndrome). By deepening understanding of the genetics that contribute to severe obesity, we aim to identify certain populations living with rare genetic disorders of obesity that may benefit from targeted therapies.

The Rhythm database enables the detection of gene variants that may contribute to the manifestation of rare genetic disorders of obesity. To help further clarify the clinical significance of these genetic data, we deploy a battery of translational research strategies, including large-scale biochemical screening studies and genetic epidemiological analyses to understand the functional and clinical relevance of observed variants. This is important for understanding the impact on the MC4R pathway.

Rhythm’s Uncovering Rare Obesity™ Program offers free* genetic testing for several rare genetic disorders of obesity to eligible patients within the U.S.
Learn more →

*Rhythm Pharmaceuticals covers cost of test only—excludes office visit, sample collection, and any other related costs to patient

For definitions to select clinical terms within this site, please visit glossary

For more information on Rhythm’s publications and presentations, please visit publications